Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955276 · ClinicalTrials.gov registry record
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
A clinical trial, sponsored by University of California, San Diego.
- Terminated
- Registry status
- 13
- Enrollment target
NCT03955276: Clinical Trial study, sponsored by University of California, San Diego.
NCT03955276 is a clinical trial that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03955276 was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular mutation profile will then be matched to existing, FDA-approved, targeted agents or to existing clinical trials using investigational agents for treatment of patients with incurable hematologic malignancies for whom no effective standard therapy exists or who have either exhausted or are intolerant of standard options.
Primary Outcome
Assess overall response rates to molecularly targeted matched treatment and physician's choice of unmatched standard-of-care treatment.
Interventions
- OTHER Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2021-01-13 |
Why NCT03955276 stopped before completion
NCT03955276 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician) is the first listed.
NCT03955276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03955276 about?
NCT03955276 is a clinical study titled "An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)". The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular m...
What is the current status of trial NCT03955276?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2019-02-07. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT03955276?
The interventions under investigation include: Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician) (OTHER).
Who is sponsoring clinical trial NCT03955276?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI